As for the efficacy of neoadjuvant immunotherapy combined with chemotherapy in EGFR-mutant patients, there is currently no prospective evidence to suggest that perioperative immunotherapy benefits patients with resectable, driver mutation-positive lung cancer (46). This evidence concerns the gene EGFR and lung carcinoma.